A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease

AimNeutralizing anti-drug antibodies (ADA) limit therapy efficacies significantly. Pegunigalsidase alfa is a newly approved drug for the treatment of Fabry disease. The increased plasma half-life due to PEGylation interferes with ADA measurements including ELISAs and serum-mediated inhibition assays...

Descripció completa

Dades bibliogràfiques

Autors principals:	Malte Lenders, Elisa Rudolph, Michael Rudnicki, Markus Cybulla, Eva Brand
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-01-01
Col·lecció:	Frontiers in Immunology
Matèries:	anti-drug antibodies drug interferences enzyme replacement therapy Fabry disease pharmacokinetics
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1724835/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!